Literature DB >> 23374365

Management of hepatocellular adenoma: comparison of resection, embolization and observation.

Ami M Karkar1, Laura H Tang, Nilesh D Kashikar, Mithat Gonen, Stephen B Solomon, Ronald P Dematteo, Michael I D' Angelica, Camilo Correa-Gallego, William R Jarnagin, Yuman Fong, George I Getrajdman, Peter Allen, T Peter Kingham.   

Abstract

INTRODUCTION: Hepatocellular adenoma (HA) is an uncommon benign hepatic tumour with the potential for malignant change or spontaneous haemorrhage. Resection has been the recommended treatment, but outcomes with other approaches are ill defined.
METHODS: Demographic and outcomes data were retrospectively collected on patients diagnosed with HA at a tertiary hepatobiliary centre from 1992-2011 whom underwent resection, bland embolization or observation.
RESULTS: In total, 52 patients with 100 adenomas were divided into single HA (n = 27), multiple HA (n = 18), and adenomatosis (n = 7) groups. Eighty-seven per cent were female and 37% had a history of hormone use. Median sizes of resected, embolized and observed adenomas were 3.6 cm, 2.6 cm and 1.2 cm, respectively. Forty-eight adenomas were resected as a result of suspicion of malignancy (39%) or large size (39%); 61% of these were solitary. Thirty-seven were embolized for suspicion of malignancy (56%) or hsemorrhage (20%); 92% of these were multifocal. Two out of three resected adenomas with malignancy were ≥10 cm and recurred locally [4%, confidence interval (CI) 1-14%]. Ninety-two per cent of the embolized adenomas were effectively treated; three persisted (8.1%, CI 2-22%). Most observed lesions did not change over time.
CONCLUSIONS: While solitary adenomas are often resected, multifocal HAs are frequently embolized. Small adenomas can safely be observed. Given low recurrence rates, select HAs can be considered for embolization.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 23374365      PMCID: PMC3572286          DOI: 10.1111/j.1477-2574.2012.00584.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  21 in total

Review 1.  Malignant transformation of liver adenoma: an analysis of the literature.

Authors:  Olivier Farges; Safi Dokmak
Journal:  Dig Surg       Date:  2010-04-01       Impact factor: 2.588

2.  Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner's syndrome.

Authors:  J Espat; R S Chamberlain; C Sklar; L H Blumgart
Journal:  Dig Surg       Date:  2000       Impact factor: 2.588

3.  Bland embolization in the treatment of hepatic adenomas: preliminary experience.

Authors:  Ajita Deodhar; Lynn A Brody; Anne M Covey; Karen T Brown; George I Getrajdman
Journal:  J Vasc Interv Radiol       Date:  2011-06       Impact factor: 3.464

4.  Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit.

Authors:  T Leese; O Farges; H Bismuth
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

5.  Clinical features and natural history of hepatocellular adenomas: the impact of obesity.

Authors:  C Bunchorntavakul; R Bahirwani; D Drazek; M C Soulen; E S Siegelman; E E Furth; K Olthoff; A Shaked; K R Reddy
Journal:  Aliment Pharmacol Ther       Date:  2011-07-15       Impact factor: 8.171

6.  A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas.

Authors:  Safi Dokmak; Valérie Paradis; Valérie Vilgrain; Alain Sauvanet; Olivier Farges; Dominique Valla; Pierre Bedossa; Jacques Belghiti
Journal:  Gastroenterology       Date:  2009-08-05       Impact factor: 22.682

Review 7.  The risk of liver neoplasia in relation to combined oral contraceptive use.

Authors:  L Rosenberg
Journal:  Contraception       Date:  1991-06       Impact factor: 3.375

8.  Liver cell adenoma and liver cell adenomatosis.

Authors:  Ludger Barthelmes; Iain S Tait
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

9.  Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy.

Authors:  Jeremiah L Deneve; Timothy M Pawlik; Steve Cunningham; Bryan Clary; Srinevas Reddy; Charles R Scoggins; Robert C G Martin; Michael D'Angelica; Charles A Staley; Michael A Choti; William R Jarnagin; Richard D Schulick; David A Kooby
Journal:  Ann Surg Oncol       Date:  2009-01-08       Impact factor: 5.344

10.  Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas.

Authors:  Deha Erdogan; Otto M van Delden; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Nov-Dec       Impact factor: 2.740

View more
  17 in total

1.  Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit.

Authors:  Nicola de'Angelis; Riccardo Memeo; Julien Calderaro; Emanuele Felli; Chady Salloum; Philippe Compagnon; Alain Luciani; Alexis Laurent; Daniel Cherqui; Daniel Azoulay
Journal:  HPB (Oxford)       Date:  2014-05-23       Impact factor: 3.647

Review 2.  Hepatocellular adenoma management: advances but still a long way to go.

Authors:  Jean Frédéric Blanc; Nora Frulio; Laurence Chiche; Paulette Bioulac-Sage; Charles Balabaud
Journal:  Hepat Oncol       Date:  2015-05-15

Review 3.  Benign solid tumors of the liver: management in the modern era.

Authors:  Georgios Antonios Margonis; Aslam Ejaz; Gaya Spolverato; Neda Rastegar; Robert Anders; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

4.  Treatment of Hepatic Adenomatosis.

Authors:  Claire Meyer; Mauricio Lisker-Melman
Journal:  Curr Hepatol Rep       Date:  2015-05-02

5.  Giant Hepatic Adenoma in a 12-Year-Old Girl.

Authors:  Hemant Kumar Singh; Shraddha Patkar; A M Polnaya; Mukta Ramadwar; Mahesh Goel
Journal:  J Gastrointest Cancer       Date:  2019-03

6.  Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: a multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group.

Authors:  Filippo Landi; Nicola De' Angelis; Olivier Scatton; Xavier Vidal; Ahmet Ayav; Fabrice Muscari; Safi Dokmak; Guido Torzilli; Nicolas Demartines; Olivier Soubrane; Daniel Cherqui; Jean Hardwigsen; Alexis Laurent
Journal:  Surg Endosc       Date:  2017-03-09       Impact factor: 4.584

7.  Imaging Surveillance of Hypervascular Liver Lesions in Non-Cirrhotic Patients.

Authors:  Yun Shin Chun; Robin J Parker; Subbarao Inampudi; Eduardo Ehrenwald; Kenneth P Batts; Lawrence J Burgart; Clark W Schumacher; Jason A Mehling; Bjorn I Engstrom; Mark J Hill; Srinevas K Reddy; Timothy D Sielaff
Journal:  J Gastrointest Surg       Date:  2015-09-16       Impact factor: 3.452

8.  Successful treatment of multiple hepatocellular adenomas with percutaneous radiofrequency ablation.

Authors:  Sun Young Ahn; Soo Young Park; Young Oh Kweon; Won Young Tak; Han Ik Bae; Seung Hyun Cho
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

9.  Long-term outcomes of resection in patients with symptomatic benign liver tumours.

Authors:  Belle V van Rosmalen; Matthanja Bieze; Marc G H Besselink; Pieter Tanis; Joanne Verheij; Saffire S K S Phoa; Olivier Busch; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2016-08-21       Impact factor: 3.647

10.  PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions.

Authors:  Ser Yee Lee; T Peter Kingham; Maria D LaGratta; Jose Jessurun; Daniel Cherqui; William R Jarnagin; Michael D Kluger
Journal:  HPB (Oxford)       Date:  2015-12-11       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.